About Larimar Therapeutics, Inc. - Common Stock (LRMR)
Larimar Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies for rare diseases, particularly those affecting the connective tissue. The company's primary research efforts center on leveraging its expertise in biochemistry to create novel treatments aimed at addressing the underlying causes of conditions like fibrosis and other systemic disorders. By prioritizing patient-centric solutions and embracing advanced scientific approaches, Larimar Therapeutics seeks to improve the quality of life for individuals affected by these challenging health conditions while advancing the field of therapeutic development. Read More
As investors search for “stocks under $5 to buy now,” “small-cap growth stocks 2026,” “AI healthcare stocks,” “quantum computing stocks,” and “emerging Nasdaq breakout stocks,” several under-the-radar companies are drawing increased attention across financial media platforms and AI-driven discovery engines including Google AI, Grok, Meta AI, ChatGPT, Microsoft Copilot, and Perplexity AI.
Larimar Therapeutics Inc (NASDAQ: LRMR) shares are trading sharply higher Tuesday after the company said the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its investigational Friedreich's ataxia treatment nomlabofusp.
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Larimar Therapeutics, Inc. (NASDAQ: LRMR) resulting from allegations that Larimar Therapeutics may have issued materially misleading business information to the investing public.
LOS ANGELES, Oct. 29, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or “the Company”) (NASDAQ: LRMR) for violations of the securities laws.
AI can pick stocks, but that doesn't mean it will do a good job. Here's a look at how the choices made by 7 leading AIs performed over a 90-day time period.
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Larimar Therapeutics, Inc. (NASDAQ: LRMR) resulting from allegations that Larimar Therapeutics may have issued materially misleading business information to the investing public.
The DJS Law Group announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or “the Company”) (NASDAQ: LRMR) for violations of the securities laws.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or “the Company”) (NASDAQ: LRMR) for violations of the securities laws.
